Slides From Leveraging GLP-1 Receptor Agonist Options to Advance Glycemic Goals in Type 2 Diabetes

Learn about the appropriate use of GLP-1 RAs to address elevated A1C, obesity, and CV risk, as well as strategies to improve tolerability and adherence.
John J. Russell, MD
Neil Skolnik, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.40 MB
Released: December 23, 2019

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Novo Nordisk Inc.

Related Content

Kristina Utzschneider, MD: Incretins and GLP-1 RAs for weight loss–thoughts on dosing, switching, nausea, vomiting, pancreatitis, gallstones

Kristina M. Utzschneider, MD Released: April 12, 2021

Webcast from ENDO 2021, learn how to look for and manage the many late endocrine effects of childhood cancer and its treatments

Wassim Chemaitilly, MD Laurie E. Cohen, MD Danielle N. Friedman, MD, MS Steven G. Waguespack, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits ABIM MOC: maximum of 1.5 Medical Knowledge MOC point(s) Registered Nurses: 1.5 Nursing contact hours Pharmacists: 1.5 contact hours (0.15 CEUs) Released: March 22, 2021 Expired: February 28, 2022

Webcast from ENDO 2021: CCO and the Endocrine Society metabolic adaptations in obesity, value of sustained weight loss, and latest evidence for incretin-based therapies

Laurie E. Cohen, MD Randy J. Seeley, PhD Steven G. Waguespack, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Pharmacists: 1.5 contact hours (0.15 CEUs) Released: March 20, 2021 Expired: March 31, 2022

Slides from CCO and the Endocrine Society: Learn how to look for and manage the many late endocrine effects of childhood cancer and its treatments

Wassim Chemaitilly, MD Laurie E. Cohen, MD Danielle Novetsky Friedman, MD, MS Steven G. Waguespack, MD Released: March 18, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue